Transcription of Emerging Treatment Options for Relapsed and Refractory ...
{{id}} {{{paragraph}}}
Example: quiz answers
Emerging Treatment Options for Relapsed and Refractory ...
Clinical Roundtable MonographModeratorDavid S. Siegel, MD, PhDChiefMyeloma DivisionJohn Theuer Cancer CenterHackensack, New JerseyDiscussantsRavi Vij, MDAssociate ProfessorOncology DivisionWashington University in St. LouisSt. Louis, MissouriAndrzej J. Jakubowiak, MD, PhDAssociate ProfessorDepartment of Internal MedicineDirectorMyeloma Program and myeloma ClinicUniversity of MichiganAnn Arbor, MichiganClinical Advances in Hematology & Oncology April 2011 Emerging Treatment Options for Relapsed and Refractory multiple MyelomaAbstract: multiple myeloma is a major hematologic malignancy, with an incidence of over 20,000 new diagnoses in the United States each year. Historically, a lack of effective therapies led to a poor patient prognosis. However, the introduction of new agents over the past decade has improved the Treatment landscape for these patients, resulting in improved responses and prolonged progression-free and overall survival.
Emerging Treatment Options for Relapsed and Refractory Multiple Myeloma Abstract: Multiple myeloma is a major hematologic malignancy, with an incidence of over 20,000 new diagnoses
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Panobinostat for the Treatment of Multiple Myeloma, Multiple myeloma, Regimens, The treatment of multiple myeloma, Myeloma, Treatment regimens, Understanding Multiple Myeloma, Its Treatment, NCCN Clinical Practice Guidelines in Oncology, Treatment, MULTIPLE MYELOMA TREATMENT REGIMENS, MULTIPLE MYELOMA CHEMOTHERAPY REGIMENS Part, Hematopoietic Stem-Cell Transplantation for Multiple, Hematopoietic Stem-Cell Transplantation for Multiple Myeloma